1135-39-3

Basic information

• Product Name: Butanoic acid, 3-hydroxy-, phenylmethyl ester
• CAS NO: 1135-39-3
• Molecular Formula: C11H14O3
• Molecular Weight: 194.23
• Mol File: 1135-39-3.mol
• Article Data: 16

Chemical Properties

• CAS DataBase Reference: Butanoic acid, 3-hydroxy-, phenylmethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Butanoic acid, 3-hydroxy-, phenylmethyl ester(1135-39-3)
• EPA Substance Registry System: Butanoic acid, 3-hydroxy-, phenylmethyl ester(1135-39-3)

Safety Data

• Hazardous Substances Data: 1135-39-3(Hazardous Substances Data)

Upstream product

• 5396-89-4 benzyl acetoacetate 
• 100-39-0 benzyl bromide 
• 300-85-6 3-Hydroxybutyric acid 
• 100-51-6 benzyl alcohol 
• 140-11-4 Benzyl acetate 
• 150-83-4 sodium DL-3-hydroxybutyrate 
• 75-07-0 acetaldehyde 

Downstream Products

• 1422974-92-2 C₃₄H₄₆O₇ 
• 419542-77-1 benzyl 3-{[tert-butyl(dimethyl)silyl]oxy}butanoate 
• 300-85-6 3-Hydroxybutyric acid 
• 71338-71-1 benzyl (E)-2-butenoate 

Relevant articles and documents

Novel degradable poly(ethylene glycol) hydrogels for controlled release of protein

Hydrogels have become increasingly important in the biomedical field. This paper describes synthesis and characterization of two types of novel degradable poly(ethylene glycol) (PEG) hydrogels with potential utility as delivery carriers for bioactive drug

CARRIER-LINKED PRODRUGS HAVING REVERSIBLE CARBOXYLIC ESTER LINKAGES

The invention provides a carrier-linked prodrugs, wherein the biologically active moieties comprise at least one carboxylic acid and wherein the linkage between the drug moiety and linker is in the form of an ester wherein the hydroxyl group required for ester formation is provided by the linker moiety and the carboxyl group required for ester formation is provided by the drug moiety. The hydroxyl group of the linker is sterically hindered by the presence of an alkyl or aryl group on the carbon directly bound to or adjacent to the carbon carrying the hydroxyl group (a-carbon). The steric effect of the alkyl or aryl group enables greater control of the rate of hydrolytic degradation of such carrier-linked prodrugs.

Carrier-linked treprostinil prodrugs

The present invention relates to prodrugs or a pharmaceutically acceptable salt thereof comprising a covalent treprostinil carrier conjugate as well as pharmaceutical composition comprising said compounds. The compounds may be used as medicaments, especially for diseases or disorders which can be treated by treprostinil, such as pulmonary arterial hypertension (PAH).

CARRIER-LINKED TREPROSTINIL PRODRUGS

The present invention relates to prodrugs or a pharmaceutically acceptable salt thereof comprising a covalent treprostinil carrier conjugate as well as pharmaceutical composition comprising said compounds. The compounds may be used as medicaments, especially for diseases or disorders which can be treated by treprostinil, such as pulmonary arterial hypertension (PAH).